2024-03-08 16:00Financial Performance - The company reported a basic earnings per share of CNY 2.44 for 2023, a 134.62% increase compared to CNY 1.04 in 2022[24]. - The diluted earnings per share also stood at CNY 2.44, reflecting the same 134.62% growth year-over-year[24]. - The net profit attributable to shareholders was CNY 416,000,000, which represents 40.09% of the total profit allocated for cash dividends[9]. - The company's operating revenue for 2023 reached approximately ¥2.65 billion, representing a 24.59% increase compared to ¥2.13 billion in 2022[46]. - Net profit attributable to shareholders increased by 130.58% to approximately ¥416.12 million from ¥180.47 million in the previous year[46]. - The net profit attributable to shareholders after deducting non-recurring gains and losses grew by 141.52%, amounting to approximately ¥383.41 million compared to ¥158.75 million in 2022[46]. - The net cash flow from operating activities surged by 174.30% to approximately ¥634.45 million, up from ¥231.30 million in the previous year[46]. - Total assets as of the end of 2023 were approximately ¥7.11 billion, a 3.09% increase from ¥6.89 billion at the end of 2022[46]. - The net assets attributable to shareholders increased by 2.46% to approximately ¥5.65 billion from ¥5.51 billion in 2022[46]. - Total revenue for 2023 reached CNY 2,645,068,738.47, an increase of 25.11% compared to the previous year[79]. - The overall gross profit margin for the main business reached 70.46%, an increase of 1.51 percentage points from the previous year[104]. Dividend Distribution - The company plans to distribute a cash dividend of CNY 10.00 per 10 shares, totaling CNY 166,833,930.00[9]. Research and Development - Research and development expenses accounted for 8.29% of operating revenue, a slight decrease of 0.26 percentage points from 8.55% in 2022[24]. - Research and development expenses amounted to CNY 220,098,318.01, a 20.81% increase from CNY 182,191,781.51 in the previous year, reflecting the company's commitment to innovation[75]. - The company has established an integrated R&D system across China, the US, the UK, France, and Israel, enhancing its technological capabilities and market competitiveness[64]. - The company is focusing on high-end implantable biomaterials, which require complex R&D and have a long development cycle[130]. - The company has several products in various stages of development, including new types of biological gels and cross-linked hyaluronic acid gels[132]. Market Expansion and Product Development - The company is actively expanding its product line in the medical aesthetics sector, including investments in RF and laser medical devices, as well as home-use instruments and botulinum toxin products[66]. - The company is focused on international expansion and has acquired several overseas companies to facilitate the transfer of advanced technologies and products to the domestic market[73]. - The company anticipates continued growth in the medical beauty market, projected to achieve a compound annual growth rate of 15%-20% over the next five years[94]. - The company is leveraging its multi-brand product line and cost advantages to adapt to the new marketing landscape post-volume procurement in the ophthalmology sector[143]. Sales and Revenue Breakdown - Revenue from ophthalmic products was CNY 928,214,432.86, a decrease of 20.57% year-on-year, with a gross margin of 59.11%[79]. - Revenue from medical beauty and wound care products increased by 41.27% to CNY 1,056,860,493.91, with a gross margin of 77.45%[79]. - Revenue from mainland China was CNY 2,191,972,736.84, up 28.20% year-on-year, with a gross margin of 73.65%[79]. - Direct sales accounted for CNY 1,321,405,596.97 in revenue, an increase of 28.49%, with a gross margin of 77.77%[79]. Operational Efficiency - The company has established a procurement center to enhance operational efficiency and reduce costs, focusing on centralized procurement of raw materials and equipment[162]. - The company has entered into significant procurement and sales contracts during the reporting period, enhancing its operational capabilities[82]. Future Outlook - The company’s future outlook includes continued investment in R&D and potential market expansion strategies[24]. - The company is exploring advanced technologies and products in ophthalmology, medical aesthetics, orthopedics, and surgery to ensure sustainable long-term development[147]. Corporate Governance - The company has no non-operating fund occupation by controlling shareholders or related parties[11]. - The company’s financial report has been confirmed as true, accurate, and complete by its management team[8].